Navigation Links
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Date:4/30/2009

INFORM-1.

Financial; Further Strengthening the Balance Sheet

  • On February 19, 2009, InterMune completed a follow-on public offering of 4,025,000 shares of common stock, including the underwriters' over-allotment, at an offer price of $16.35 per share. Net proceeds to InterMune were approximately $63.4 million after deduction of underwriting fees and other related expenses.
  • On April 3, 2009, InterMune reported that it would retire approximately $32.3 million of its .25% Convertible Senior Notes due 2011 by exchanging Notes held by certain of its debt holders for shares of the company's common stock. A total of approximately 2.1 million shares of common stock have been issued in connection with the transaction.

2009 Key Project Guidance

The company provided the following guidance on its key development projects, pirfenidone and ITMN-191.

    PIRFENIDONE
        Milestones and Key Events                             Expected  Date

    -- Presentation of CAPACITY results at ATS                  May 19
    -- Submission of pirfenidone NDA to FDA                     Summer
    -- Submission of pirfenidone MAA to EMEA                    Year-End


    ITMN-191
        Milestones and Key Events                             Expected  Date

    -- Phase 2b initiation by Roche ($20 million
        payment to InterMune)                                   Summer 2009
    -- Presentation of additional cohorts of INFORM-1
        at AASLD                                                Q4, 2009 *
    -- Rapid Viral Response (RVR) data from Phase 2b
        (12-week regimen)                                       Q4'09 or Q1'10
    * Subject to acceptance of scientific abstract

Guidance for 2009 Revenue and Expenses

Th
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 30
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. InterMune to Present at Canaccord Adams Hepatitis C Conference
4. InterMune to Present at Citis 4th Annual Biotech Day
5. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
6. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
7. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
8. InterMune Announces Issuance of U.S. Patent for ITMN-191
9. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
10. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
11. InterMune to Present at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 ­ RedBrick Health ... behavior change technology, today announces that EmblemHealth , ... and wellness company, is now providing the RedBrick Compass ... coaching program, to all of its members. EmblemHealth is ...
(Date:1/15/2014)... NY (PRWEB) January 15, 2014 The Microcompetition ... a major disease. One of these latent viruses is the ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory ... theory, a study found that RA patients have high concentrations ...
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... Clinton will,participate as one of the main speakers at the ... in Sao Paulo, Brazil. The event is organized by the,Brazilian ... gatherings focused on biofuels in the world. , ... a second term,in six decades. After leaving the White House, ...
... - Aegera Therapeutics is pleased to announce the ... for AEG33773, a novel, orally bio-available small molecule ... neuropathy. , The Phase 2a study, entitled A ... and Efficacy of AEG33773 versus Placebo in Patients ...
... announced successful,completion of the single-day oral dosing part ... patients with its new anti-cancer drug AXL1717,an,insulin-like growth ... the closely related insulin receptor. The study is ... The results showed that a single-day,dosing of AXL1717 ...
Cached Biology Technology:President Bill Clinton to Speak at the Ethanol Summit in Brazil 2Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain 2Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB 2
(Date:4/18/2014)... crystallography and nuclear magnetic resonance imaging (NMR) to gain ... such efforts have long been hampered by the fact ... and often in ordered and crystalized form to be ... into the structure of most molecules. , Harvard researchers, ... of the past. , A team of scientists, ...
(Date:4/18/2014)... the past 20 years, researchers have published soil organic ... have suggested that soil organic carbon can be sequestered ... to no-till systems. However, there is a growing body ... and soybean rotations without cover crops, small grains, and ... at the published rates. , "Some studies have shown ...
(Date:4/18/2014)... Durham, NC Seeds that sprout as soon as they,re ... plants need to be more careful. In the wild, a ... rainy day would risk disaster. More than just an insurance ... out that seed dormancy has long-term advantages too: Plants ... give rise to more species, finds in a team of ...
Breaking Biology News(10 mins):MRI, on a molecular scale 2MRI, on a molecular scale 3Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4Plants with dormant seeds give rise to more species 2
... may aid the quest for accurate, low-cost genomic sequencing, according ... by Stuart Lindsay and his collaborators at the Biodesign Institute ... an electron, can cross a barrier, when, according to classical ... Unraveling the DNA sequences of the human genome a ...
... N.J., March 4 BIO-key International, Inc. (OTC Bulletin ... finger-based biometric identification solutions, today announced that on or ... United States District Court for the Southern District of ... two of the Company,s investors, Longview Special Finance, Inc. ...
... Detects Faces in Motion, Matches with Watch-list ... Lithuania, March 9 Neurotechnology, a provider ... the availability of VeriLook Surveillance SDK, a ... using live video streams from high-resolution digital ...
Cached Biology News:Covering the bases: Quantum effect may hold promise for low-cost DNA sequencing, sensor applications 2Covering the bases: Quantum effect may hold promise for low-cost DNA sequencing, sensor applications 3Covering the bases: Quantum effect may hold promise for low-cost DNA sequencing, sensor applications 4BIO-key to Respond in Court to a Lawsuit Filed by Two Investors 2BIO-key to Respond in Court to a Lawsuit Filed by Two Investors 3VeriLook Surveillance SDK Provides Real-Time Face Identification Using Video Surveillance Cameras 2VeriLook Surveillance SDK Provides Real-Time Face Identification Using Video Surveillance Cameras 3
Homo sapiens olfactomedin 1, transcript variant 3...
RABBIT ANTI QUINOLINIC ACID...
Coverslips for Microarrays, 1. *Category: MICROARRAY ACCESSORIES....
Agarase cleaves agarose to neoagaro-oligosaccharides, and is used for,quantitative, gentle recovery of DNA from low melting point agarose....
Biology Products: